AI Article Synopsis
- Liver fibrosis is the key factor linked to liver-related deaths in non-alcoholic fatty liver disease (NAFLD).
- There are currently no approved treatments for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis.
- The MAESTRO-NASH trial showed that resmetirom, a selective THR-β agonist, effectively treats MASH and liver fibrosis over 52 weeks.
Article Abstract
The most important factor associated with liver-related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison et al. demonstrated the efficacy of resmetirom, a selective THR-β agonist, for the treatment of MASH and liver fibrosis at 52 weeks.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.03.013 | DOI Listing |
Publication Analysis
Top Keywords
liver fibrosis
12
treatment metabolic
8
metabolic dysfunction-associated
8
dysfunction-associated steatohepatitis
8
mash liver
8
resmetirom long-awaited
4
long-awaited treatment
4
liver
4
steatohepatitis liver
4
liver fibrosis?
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!